PIK3CA and neoplasm: Importantly, PI3Kγ inhibition can synergize with anti-PD-1 to reduce tumor growth, extending survival [421,422], and pan-PI3K inhibition can be used to overcome resistance to immune checkpoint inhibitors [423].